AD‐associated CSF biomolecular changes are attenuated in KL‐VS heterozygotes-Reference-Cited by-同舟云学术

AD‐associated CSF biomolecular changes are attenuated in KL‐VS heterozygotes

Published:2022-01 Issue:1 Volume:14 Page:
ISSN:2352-8729
Container-title:Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
language:en
Short-container-title:Alz & Dem Diag Ass & Dis Mo

Author:

Driscoll Ira¹²³,Ma Yue²,Lose Sarah R.¹²,Gallagher Catherine L.⁴⁵,Johnson Sterling C.¹²⁴,Asthana Sanjay¹²⁴,Hermann Bruce P.¹²⁵,Sager Mark A.¹²,Blennow Kaj⁶⁷,Zetterberg Henrik⁶⁷⁸⁹,Carlsson Cynthia M.¹²⁴,Engelman Corinne D.¹²¹⁰,Dubal Dena B.¹¹,Okonkwo Ozioma C.¹²⁴

Affiliation:

1. Wisconsin Alzheimer's Disease Research Center University of Wisconsin‐Madison Madison Wisconsin USA

2. Wisconsin Alzheimer's Institute Madison Wisconsin USA

3. Department of Psychology University of Wisconsin‐Milwaukee Milwaukee Wisconsin USA

4. Geriatric Research Education and Clinical Center William S. Middleton VA Hospital Madison Wisconsin USA

5. Department of Neurology University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA

6. Department of Psychiatry and Neurochemistry Institute of Neuroscience and Physiology Sahlgrenska Academy at the University of Gothenburg Göteborg Sweden

7. Clinical Neurochemistry Laboratory Sahlgrenska University Hospital Mölndal Sweden

8. Department of Neurodegenerative Disease UCL Institute of Neurology Queen Square London UK

9. UK Dementia Research Institute at UCL London UK

10. Departments of Population Health Sciences University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA

11. Department of Neurology and Weill Institute for Neurosciences University of California California San Francisco USA

Publisher

Wiley

Subject

Psychiatry and Mental health,Neurology (clinical)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/dad2.12383

Reference50 articles.

1. 2018 Alzheimer's disease facts and figures

2. The genetic landscape of Alzheimer disease: clinical implications and perspectives

3. Drug treatments in Alzheimer’s disease

4. Alzheimer's disease

5. Ageing as a risk factor for neurodegenerative disease